سعر بريفينوزيا 150مجم محلول وريدي 2026

Fosaprepitant 150 mg powder for solution for intravenous infusion (NK1 receptor antagonist prodrug of aprepitant), 1 vial.

• Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy, as part of combination therapy with a corticosteroid and a 5-HT3 antagonist.Population: Adults and paediatric patients aged 6 months and olderEuropean Medicines Agency (EPAR product information)

• Hypersensitivity to fosaprepitant, polysorbate 80 or any excipient.International label, same formulation · European Medicines Agency (EPAR product information)
• Co-administration with pimozide, terfenadine, astemizole or cisapride.International label, same formulation · European Medicines Agency (EPAR product information)

• Hormonal contraceptive efficacy may be reduced during and for 28 days after administration; non-hormonal back-up contraception is advised during treatment and for 2 months after the last dose.International label, same formulation · European Medicines Agency (EPAR product information)

• No clinical data on exposed pregnancies; should not be used during pregnancy unless clearly necessary.International label, same formulation · European Medicines Agency (EPAR product information)
• Aprepitant is excreted in rat milk; breast-feeding is not recommended during treatment.International label, same formulation · European Medicines Agency (EPAR product information)

• Fosaprepitant: Prodrug converted to aprepitant, a selective high-affinity substance P/neurokinin-1 receptor antagonist.